GSK ’s Shingrix receives approval in Canada to prevent shingles
GlaxoSmithKline ’s (GSK) non-live, recombinant sub-unit, adjuvanted vaccine Shingrix has received approval from Health Canada to prevent shingles (herpes zoster) in people aged 50 or older.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Canada Health | Herpes | Pharmaceuticals | Shingles | Shingles (Herpes Zoster) Vaccine | Vaccines | Varicella-Zoster Virus Vaccine